Liquisolid technique using tween 80 and sodium starch glycolate to enhance the solubility and dissolution rate of an antihypertensive drug

Ekta Naik, Divya Harmalkar, Soraiya Godinho, Lalit Kumar, Shaila Lewis, Rupesh K. Shirodkar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Lacidipine (LCDP), a BCS class II calcium channel blocker, is used as antihypertensive agent. LCDP possesses low aqueous solubility and also undergoes extensive first pass metabolism resulting in oral bioavailability of 10%. The present study was aimed to enhance the solubility and hence dissolution rate of LCDP by formulating into liquisolid compacts. LCDP liquisolid compacts were formulated using avicel PH 102, tween 80, aerosil 200 and sodium starch glycolate. A mathematical model was adopted to determine the suitable quantity of carrier and coating materials. The formulated tablets were evaluated for post compression parameters. Liquisolid tablets showed high drug release as compared to the pure drug. The optimized formulation exhibited 99.89 ± 0.162% of drug release within 45 min. Stability studies confirmed the stability of optimized formulation. Present study thus concluded that the liquisolid is a favourable technique to improve the solubility and drug release of LCDP.

Original languageEnglish
Pages (from-to)717-726
Number of pages10
JournalLatin American Journal of Pharmacy
Volume37
Issue number4
Publication statusPublished - 01-01-2018

Fingerprint

Polysorbates
Solubility
Antihypertensive Agents
Tablets
Calcium Channel Blockers
Cellulose
Silicon Dioxide
Biological Availability
Theoretical Models
lacidipine
sodium starch glycolate
Pharmaceutical Preparations
Drug Liberation

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Drug Discovery

Cite this

@article{a8509d0b1a0d4b1d983ac38bb224a994,
title = "Liquisolid technique using tween 80 and sodium starch glycolate to enhance the solubility and dissolution rate of an antihypertensive drug",
abstract = "Lacidipine (LCDP), a BCS class II calcium channel blocker, is used as antihypertensive agent. LCDP possesses low aqueous solubility and also undergoes extensive first pass metabolism resulting in oral bioavailability of 10{\%}. The present study was aimed to enhance the solubility and hence dissolution rate of LCDP by formulating into liquisolid compacts. LCDP liquisolid compacts were formulated using avicel PH 102, tween 80, aerosil 200 and sodium starch glycolate. A mathematical model was adopted to determine the suitable quantity of carrier and coating materials. The formulated tablets were evaluated for post compression parameters. Liquisolid tablets showed high drug release as compared to the pure drug. The optimized formulation exhibited 99.89 ± 0.162{\%} of drug release within 45 min. Stability studies confirmed the stability of optimized formulation. Present study thus concluded that the liquisolid is a favourable technique to improve the solubility and drug release of LCDP.",
author = "Ekta Naik and Divya Harmalkar and Soraiya Godinho and Lalit Kumar and Shaila Lewis and Shirodkar, {Rupesh K.}",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "37",
pages = "717--726",
journal = "Latin American Journal of Pharmacy",
issn = "0326-2383",
publisher = "Colegio de Farmaceuticos de la Provincia de Buenos Aires",
number = "4",

}

Liquisolid technique using tween 80 and sodium starch glycolate to enhance the solubility and dissolution rate of an antihypertensive drug. / Naik, Ekta; Harmalkar, Divya; Godinho, Soraiya; Kumar, Lalit; Lewis, Shaila; Shirodkar, Rupesh K.

In: Latin American Journal of Pharmacy, Vol. 37, No. 4, 01.01.2018, p. 717-726.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Liquisolid technique using tween 80 and sodium starch glycolate to enhance the solubility and dissolution rate of an antihypertensive drug

AU - Naik, Ekta

AU - Harmalkar, Divya

AU - Godinho, Soraiya

AU - Kumar, Lalit

AU - Lewis, Shaila

AU - Shirodkar, Rupesh K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Lacidipine (LCDP), a BCS class II calcium channel blocker, is used as antihypertensive agent. LCDP possesses low aqueous solubility and also undergoes extensive first pass metabolism resulting in oral bioavailability of 10%. The present study was aimed to enhance the solubility and hence dissolution rate of LCDP by formulating into liquisolid compacts. LCDP liquisolid compacts were formulated using avicel PH 102, tween 80, aerosil 200 and sodium starch glycolate. A mathematical model was adopted to determine the suitable quantity of carrier and coating materials. The formulated tablets were evaluated for post compression parameters. Liquisolid tablets showed high drug release as compared to the pure drug. The optimized formulation exhibited 99.89 ± 0.162% of drug release within 45 min. Stability studies confirmed the stability of optimized formulation. Present study thus concluded that the liquisolid is a favourable technique to improve the solubility and drug release of LCDP.

AB - Lacidipine (LCDP), a BCS class II calcium channel blocker, is used as antihypertensive agent. LCDP possesses low aqueous solubility and also undergoes extensive first pass metabolism resulting in oral bioavailability of 10%. The present study was aimed to enhance the solubility and hence dissolution rate of LCDP by formulating into liquisolid compacts. LCDP liquisolid compacts were formulated using avicel PH 102, tween 80, aerosil 200 and sodium starch glycolate. A mathematical model was adopted to determine the suitable quantity of carrier and coating materials. The formulated tablets were evaluated for post compression parameters. Liquisolid tablets showed high drug release as compared to the pure drug. The optimized formulation exhibited 99.89 ± 0.162% of drug release within 45 min. Stability studies confirmed the stability of optimized formulation. Present study thus concluded that the liquisolid is a favourable technique to improve the solubility and drug release of LCDP.

UR - http://www.scopus.com/inward/record.url?scp=85046999212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046999212&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 717

EP - 726

JO - Latin American Journal of Pharmacy

JF - Latin American Journal of Pharmacy

SN - 0326-2383

IS - 4

ER -